ORANGE COUNTY, Calif., May 13 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC - News), a leading developer, manufacturer, and marketer of products that simplify, automate, and innovate complex biomedical testing, today announced that the Federal Trade Commission has terminated its review under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended, of the company’s pending acquisition of Olympus Corporation’s lab-based diagnostics business.
As previously announced on February 27, 2009, Beckman Coulter and Olympus announced that they had entered into a definitive agreement under which Beckman Coulter will acquire the diagnostic systems portion of Olympus’ Life Sciences business for approximately USD $780 million.
This transaction is expected to close in the third quarter of 2009 and is subject to certain government approvals outside the United States, the negotiation of certain ancillary agreements, the delivery of and agreement to disclosure schedules and transition arrangements as well as other customary conditions.
About Beckman Coulter
Beckman Coulter, Inc., based in Fullerton, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of consumable supplies, (including reagent test kits), service and operating-type lease payments, represent about 78% of the company’s 2008 revenue of $3.1 billion. For more information, visit www.beckmancoulter.com.
Contacts: Investor Relations Cynthia Skoglund (714) 773-7620
Media Relations Mary Luthy (714) 773-7964
